SEC Tracker
Get the app

Pacira BioSciences PCRX

Pacira BioSciences (PCRX) announces acquisition by Viatris Inc.

SC TO-C filing

Form
Schedule TO-C
Filed
Importance
Routine
  1. Viatris Inc. plans to acquire Pacira BioSciences, Inc.
  2. The acquisition includes all outstanding shares of Pacira's common stock.
  3. The tender offer is expected to be accretive to Viatris's portfolio.
  4. The transaction is subject to regulatory approvals and shareholder approvals.

Written from the Schedule TO-C on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Pacira BioSciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float $300M to $2B, nearest public float first, as each company reports it on its annual report cover.

  1. Phibro Animal Health PAHC public float $764M, Dec 31, 2025
  2. Syndax Pharmaceuticals SNDX public float $799M, Jun 30, 2025
  3. Geron GERN public float $861M, Jun 30, 2025
  4. Anaptysbio ANAB public float $633M, Dec 31, 2025
  5. Amphastar Pharmaceuticals AMPH public float $633M, Jun 30, 2025